Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients

Geraldine A Finlay, Kenneth J Russell, Kevin J McMahon, Elizabeth M D’arcy, James B Masterson, Muiris X FitzGerald, Clare M O’Connor

Abstract

Background – Matrix degradation in emphysema has long been attributed to the action of neutrophil elastase (NE). More recently a role for other proteases, particularly the matrix metalloproteinases (MMPs), in the pathogenesis of this disease has been proposed. To date, however, the presence of MMPs in the lungs of patients with emphysema has not been demonstrated.

Methods – Samples of bronchoalveolar lavage (BAL) fluid from 10 patients with emphysema and from control subjects matched for sex and current smoking status were assessed for collagenase, gelatinase, and NE activity. Pulmonary function tests and computed tomographic (CT) scans were carried out on all study subjects.

Results – Collagenase activity was detected in BAL fluid samples from all emphysematous patients but in only one smoking control (p<0.001). Gelatinase B was present in six patients and in two smoking controls (p<0.03). The concomitant presence of gelatinase B in complex with lipocalin (NGAL) in the gelatinase positive samples suggests that the neutrophil is a significant source of the gelatinase B observed. NE was detected in six of the 10 patients with emphysema and in two smoking controls (p<0.01), indicating that collagenase was more useful in discriminating between disease and control groups than either NE or gelatinase B. No relationship was observed between any of the enzymes measured and pulmonary function or CT density score.

Conclusions – This study demonstrates, for the first time, the presence of increased levels of matrix metalloproteinases in the lungs of patients with emphysema and suggests that, in BAL fluid, collagenase activity may be a better indicator of the presence of emphysema than elastase.

Pulmonary emphysema is a condition of the lung characterised by progressive destruction and loss of functioning alveoli. The mechanisms involved in extracellular matrix (ECM) damage are not precisely known but a significant body of evidence supports the protease-antiprotease theory which postulates that an excess of proteolytic activity over the inhibitory capacity of the lung leads to parenchymal destruction. Most studies to date have focused on the role of neutrophil elastase (NE) as the major effector protease involved. More recently, however, there has been considerable speculation on the potential involvement of other proteases, particularly the matrix metalloproteinases (MMPs), in matrix degradation in emphysema.

The MMPs are a highly homologous family of endopeptidases which are collectively capable of breaking down all the constituents of the alveolar ECM, including collagen, elastin, proteoglycans, laminin, and fibronectin. They are produced by a range of stromal cells and by two of the major inflammatory cells implicated in emphysema – the alveolar macrophage and the neutrophil. Indirect evidence that MMPs may play a part in tissue destruction in emphysema comes from a number of studies. Janoff et al demonstrated that the elastolytic activity of bronchoalveolar lavage (BAL) fluid from smokers was significantly inhibited by metal chelating agents and concluded that MMPs were responsible for almost 50% of the activity measured. More recently, D’Armiento et al have described the development of emphysema in transgenic mice expressing human interstitial collagenase (MMP-1) in their lungs, lending support to the theory that MMPs contribute to the pathogenesis of emphysema. To date, however, the presence of MMPs in the lungs of patients with emphysema has not been demonstrated.

The aim of this study was to determine whether increased quantities of MMPs are present in the lungs of patients with emphysema. Levels of two of the major MMPs, collagenase and gelatinase, were assessed in epithelial lining fluid (ELF) from patients with emphysema and compared with levels in a control group. The level of NE in the ELF was also assessed in both groups.
Methods

STUDY POPULATION
Ten patients with emphysema (all men, four smokers and six ex-smokers) aged 43–75 years were entered into the study. Criteria for selection of emphysema patients were (1) impaired pulmonary function as indicated by a forced expiratory volume in one second (FEV1) <75% of predicted normal and/or a ratio of FEV1 to forced vital capacity (FVC) of <75%, (2) high resolution computed tomographic (CT) evidence of emphysema, (3) clinical history, medical symptoms, and chest radiography consistent with the diagnosis of emphysema, and (4) no reversibility of airflow obstruction after inhalation of β2 agonists. None of the patients had received inhaled or oral steroids at the time of lavage or in the previous six weeks.

Eleven control subjects (all men, five smokers and six non-smokers) aged 43–58 years undergoing a brief general anaesthetic for minor surgery were also recruited to the study. To exclude the presence of emphysema clinical history, medical examination, chest radiography, pulmonary function tests and CT scans were carried out on all control subjects.

No subject in either the patient or control group had a history of atopy or episodic wheezing, nocturnal dyspnoea or ankle oedema. All subjects denied having significant symptoms of a respiratory tract infection in the preceding six weeks. Arterial blood gas tensions measured in all subjects whilst breathing room air showed no evidence of clinically significant hypoxaemia or hypercapnia and the serum levels of α1-proteinase inhibitor were normal in all subjects. All current smokers were lifelong smokers of at least 10 cigarettes per day and ex-smokers had ceased their habit for at least 10 years. Smokers were asked to refrain from smoking for at least 12 hours prior to lavage. Thus, in each case the diagnosis of emphysema was established or excluded and the absence of coexistent disease confirmed. All subjects gave their informed consent and the project was approved by St Vincent’s Hospital ethics committee.

BRONCHOSCOPIC EXAMINATION AND BRONCHOALVEOLAR LAVAGE
Before bronchoscopic examination patients were premedicated with intramuscular atropine (0.6 mg). The upper respiratory tract was then anaesthetised with nebulised lignocaine, patients sedated with intravenous midazolam (10 mg), and bronchoalveolar lavage was performed as previously described. Oxygen was provided for emphysematous patients by nasal catheter at 2 l/min during bronchoscopy and electrocardiographic rhythm was continuously monitored. Control subjects received intravenous suxamethonium and propofol and were rapidly intubated and anaesthetised with isoflurane, immediately following which bronchoscopy was performed prior to any surgical procedure.

Samples of BAL fluid were processed under sterile conditions within one hour of collection.

Viability of cells recovered by centrifugation was over 90% in all cases. Differential counts were determined on Diff-Quick stained preparations. Cell-free BAL fluid was divided into aliquots for measurement of collagenase, gelatinase, and NE. To avoid proteolysis following sampling the serine proteinase inhibitors diisopropylfluorophosphate (DIPF, 1 mM) and phenyl-methyl-sulphonylfluoride (PMSF, 1 mM) were added to the aliquots to be analysed for MMP activity. No inhibitors were added to the samples to be assessed for the presence of NE. All samples were stored at −70°C until analysis which was performed within six months of collection. For standardisation purposes the urea concentration in the serum and BAL fluid was measured in all subjects, the volume of dilution was determined, and the volume of epithelial lining fluid (ELF) was calculated. Enzyme results were expressed per ml ELF.

ENZYMATIC ANALYSIS
For measurement of collagenase activity samples of BAL fluid were concentrated × 20 by ultrafiltration on CF25 Centrilo membrane cones (Amicon Corporation, Danvers, Massachusetts, USA). Latent collagenase was activated by incubation with 1 mM p-aminophenylmercuric acetate (APMA) at 35°C for 10 minutes and collagenase activity was then determined by measuring the release of radio-labelled fragments from 14C-labelled type I collagen as previously described. Gelatin zymography was carried out on uncentrificed samples of BAL fluid as described by Overall et al. Positive standards included a neutrophil lysate and a preparation containing gelatinase A and B from gelatinase B transfected HK cells (obtained from Dr S McDonnell, Dublin City University, Dublin, Ireland). Densitometry was carried out on negative images of the zymograms using the GDS-8000 Complete Gel Imaging System (Phoretix International, Newcastle upon Tyne, UK). The density of bands in individual samples was standardised to the gelatinase A/gelatinase B positive standard on the corresponding zymogram. Units of gelatinase activity were expressed as arbitrary densitometric units per ml ELF. To assess NE activity, samples of lavage fluid were concentrated × 20 by centrifugal evaporation (Gyrovap, Howe and Co, UK) and NE activity was measured using the specific chromogenic peptide substrate, N-methoxy-succinyl-Ala-Ala-Pro-val p-nitroanilide (MEOSAAPVPNA, Sigma, Poole, UK) at a concentration of 4.2 mM. Using an extinction coefficient of 8800/l/mmol/mc molar concentrations of peptide hydrolysed were determined and enzyme units, defined as the release of 1 M p-nitroanilide/ml/min of sample, were calculated.

STATISTICAL ANALYSIS
The non-parametric Wilcoxon’s rank sum test was used for statistical analysis of cellular and enzyme data. Regression analysis was used to correlate clinical, radiological and enzyme data.
Values were expressed as medians with absolute ranges unless otherwise stated. In all tests p values of <0.05 were taken as indicating a significant difference between the groups.

Results

BAL fluid cell profile

The total number of cells recovered in the BAL fluid did not differ between patients with emphysema (median 12.9 × 10⁶; range 1.5–36.4 × 10⁶ cells) and controls (median 10.0 × 10⁶; range 1.0–37.4 × 10⁶ cells). In both groups over 90% of cells recovered were alveolar macrophages (91.8% and 91.4% in emphysematous and control groups, respectively) and less than 2% were neutrophils (1.35% and 1.2% for emphysematous and control groups, respectively).

Collagenase activity

Collagenase was detected in all 10 patients with emphysema (median 4.41, range 1.04–6.86 U/ml ELF) but in only one control subject (3.1 U/ml ELF; p<0.001; fig 1A). There was no statistical difference in collagenase levels between smokers and non-smokers in the patient group, nor was the presence of collagenase in ELF related to age or the number of neutrophils or macrophages in the BAL fluid. No correlation was seen between the collagenase level and CT density score or pulmonary function.

Gelatinase zymography

Gelatinase was present in ELF from five patients with emphysema and two control subjects, both of whom were smokers (fig 1B). In both control and patient groups gelatin zymography showed the presence of four distinct gelatinase bands of molecular weights 92 kDa (corresponding to latent gelatinase B), 130 kDa, 220 kDa, and 270 kDa (fig 2). This banding pattern corresponded to that observed for the standard neutrophil lysate and is highly
characteristic of gelatinase released from neutrophils. The band of molecular weight 130 kDa has been characterised as gelatinase B in complex with another neutrophil secondary granule protein, lipocalin (neutrophil gelatinase associated lipocalin; NGAL), and the higher molecular weight bands as multiple forms of gelatinase B. In four patient samples additional bands (not shown) were observed at 72 kDa, which corresponds to the molecular weight of latent gelatinase A, and 63 kDa which may represent the active form of gelatinase A. Denisotometric quantitation showed significantly higher levels of gelatinase B (92 kDa) in patients (median 0.32; range 0–6.51 densitometric units/ml ELF) compared with controls (median 0; range 0–0.44 densitometric units/ml ELF; p<0.03). Within the patient group there was no difference in gelatinase B levels between smokers and ex-smokers.

**Discussion**

This study provides, for the first time, direct evidence of the presence of increased quantities of the MMPs collagenase and gelatinase in the epithelial lining fluids of emphysematous patients compared with healthy controls. All of the patients studied had demonstrable ELF collagenase activity, while collagenase was detected in the ELF from only one control subject, which suggests that ELF collagenase may be a useful discriminator for the presence of emphysema.

The origin of the collagenase activity detected in the lavage fluids of these patients is not clear. Collagenase activity was determined by degradation of a radiolabelled type I collagen substrate which is preferentially degraded by neutrophil collagenase (MMP-8). While interstitial collagenase (MMP-1) – which is produced by alveolar macrophages and interstitial cells – can also degrade type I collagen, it does so at a rate which is unlikely to be detected in the 90 minute incubation period of the assay employed. It is therefore likely that the collagenase activity measured was that of neutrophil collagenase.

Of the patients studied, 50% had detectable gelatinase in their epithelial lining fluids compared with 18% of controls. Zymographic profiles indicated that the bulk of gelatinase present in ELF is attributable to gelatinase B (MMP-9) and multiple forms of gelatinase B, a banding pattern strongly characteristic of gelatinase B of neutrophil origin. However, gelatinase B can also be secreted by alveolar macrophages and the possibility that the macrophage is another source of ELF gelatinase B in emphysema cannot be ruled out. Furthermore, gelatinase A, which is produced by interstitial cells and macrophages, was present in the ELF of four patients with emphysema.

Six of the 10 patients and two of the 11 controls had detectable NE activity in the ELF. Thus, the ability of NE to discriminate between an emphysematous patient and a healthy control was not as accurate as that observed for ELF collagenase.

These observations must be taken in the context of synergistic modulation of extracellular matrix proteolysis. In vitro, serine proteases activate latent forms of MMPs, which can also inactive tissue inhibitor of metallo-proteinases and MMPs can inactive α1-PI, a major inhibitor of NE, which suggests that interaction between MMPs and the serine proteases may be of importance in the unchecked digestion of extracellular matrix. Given that only 10–15% of smokers develop emphysema, it could be speculated that production and release of all three proteases in conjunction with each other may be one of the biological variables which renders an individual vulnerable to the development of progressive lung disease subsequent to cigarette smoking.

In conclusion, this study highlights the potential contribution of the matrix metallo-proteinases collagenase and gelatinase B, in addition to neutrophil elastase, in the pathogenesis of human emphysema. It is likely that the interaction of these potent proteases is involved in the irreversible and progressive alveolar destruction which characterises emphysema.

This work was supported by the Health Research Board of Ireland.

Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients.

G A Finlay, K J Russell, K J McMahon, E M D'arcy, J B Masterson, M X FitzGerald and C M O'Connor

*Thorax* 1997 52: 502-506
doi: 10.1136/thx.52.6.502

Updated information and services can be found at:
http://thorax.bmj.com/content/52/6/502

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Health education (1223)
- Smoking (1037)
- Tobacco use (1039)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/